Global pharmaceutical giant GSK has teamed up with Flagship Pioneering, a pioneer in biotechnology innovation, to join forces in the discovery of new treatments and vaccines. The collaboration will initially focus on respiratory diseases and immunology, with the goal of developing transformative therapies and vaccines in the coming years.
By combining the expertise of both companies, the partnership aims to accelerate scientific progress in the healthcare sector. GSK’s extensive experience and Flagship Pioneering’s innovative biotechnology ecosystem are expected to play a critical role in the development of future treatments and vaccines. In addition, healthcare professionals and researchers will have the opportunity to witness and contribute to the new treatment methods that emerge from this process.
10 New Treatments and Vaccine Targets
Under the partnership, GSK and Flagship Pioneering aim to develop 10 new treatments and vaccines. To support this goal, GSK will provide funding for preclinical stages and commit to making incremental royalty payments.
GSK’s Chief Scientific Officer Tony Wood commented on the partnership: “Together with Flagship, we will leverage the best of science and technology to rapidly bring innovative treatments and vaccines to life. By collaborating with Flagship’s experienced team and its biotechnology companies, we aim to discover groundbreaking treatments and vaccines for patients.”
Flagship Pioneering’s General Partner Paul Biondi added: “Flagship and GSK share a common vision to deliver groundbreaking treatment options for patients. This collaboration is the latest example of Flagship’s Innovation Supply Chain Partnership model, which leverages our biotechnology ecosystem to provide sustainable treatment resources in collaboration with pharmaceutical companies.”
